No abstract

No abstract

IL-2, IL-8, IL-10 and IL-12 (p40) were found to be elevated in the sera of patients with IPF. IFN-gamma was found to be decreased in the sera of patients with IPF.

No abstract

No abstract

The outbreak of the novel coronavirus disease-19 (COVID-19) has rapidly and drastically impacted worldwide the healthcare system. Despite an increasing number of recommendations becoming available in the last two months, measures adopted in radiationoncology departments to overcome this situation are rapidly changing and may differ largely based on institutional and national practices.We conducted a national survey of all radiation oncology centers in Switzerland to better understand the early impact of the COVID-19 pandemic on our discipline. MethodsA 53-questions online survey was finalized on April 6th, 2020 using available recommendations [1-8] and distributed by email on April 07th, 2020 to the representatives of the 30 Swiss radiation

No abstract

In order to test the serum levels of ICAM-1, ICAM-2 and ICAM-3 in patients with idiopathic pulmonary fibrosis (IPF), twenty patients with IPF and eleven with secondary interstitial fibrosis (SIF), as well as forty healthy volunteers (HV) were studied. Serum intracellular adhesion molecules (ICAM) 1, 2 and 3 were assessed by ELISA. Functional respiratory tests, which included spirometry and lung diffusing capacity were simultaneously performed. Median values of serum ICAM-1 and ICAM-2 were higher in the patients' than in the healthy volunteers' (HV) group: IPF group: 946.60 ng/ml and 400.14 ng/ml; SIF group: 901.58 ng/ml and 378.27 ng/ml; HV group: 308.40 ng/ml and 217.55 ng/ml, respectively (p<0.05). ICAM-3 serum levels were equal between the three groups. ICAM-2 negatively correlated to DLCO values. (p<0.005). It can be concluded that ICAM 1 and 2 are elevated in the sera of patients with pulmonary fibrosis. ICAM-2 might be associated with a more impaired clinical status.